These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1310584)

  • 21. Double-Blind, Placebo-Controlled, Randomized Phase I/IIa Study (Safety and Efficacy) with Buspirone/Levodopa/Carbidopa (SpinalonTM) in Subjects with Complete AIS A or Motor-Complete AIS B Spinal Cord Injury.
    Radhakrishna M; Steuer I; Prince F; Roberts M; Mongeon D; Kia M; Dyck S; Matte G; Vaillancourt M; Guertin PA
    Curr Pharm Des; 2017; 23(12):1789-1804. PubMed ID: 28025945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.
    Hely MA; Morris JG; Reid WG; O'Sullivan DJ; Williamson PM; Rail D; Broe GA; Margrie S
    J Neurol Neurosurg Psychiatry; 1994 Aug; 57(8):903-10. PubMed ID: 8057111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa/carbidopa to improve motor function subsequent to brain tumor excision.
    Ennis JD; Harvey D; Ho E; Chari V; Graham A; Nesathurai S
    Am J Phys Med Rehabil; 2013 Apr; 92(4):307-11. PubMed ID: 23221674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic treatment of parkinsonian tremor.
    Koller WC
    Arch Neurol; 1986 Feb; 43(2):126-7. PubMed ID: 3947248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Controlled study on the possibilities of L-dopa in the residual extrapyramidal syndrome caused by neuroleptics].
    Gutiérrez M; Alpert M; Guimón J; Friedhoff AJ; Veramendi V
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1979; 7(3):181-8. PubMed ID: 382762
    [No Abstract]   [Full Text] [Related]  

  • 26. [Pathogenetic treatment of various hereditary extrapyramidal disorders with new drugs].
    Markowa ED; Hausmanowa-Petrusewicz I; Alijewa LM; Friedman A; Insarowa NG
    Neurol Neurochir Pol; 1981; 15(4):403-6. PubMed ID: 7329507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levodopa-carbidopa may improve vision loss in indirect traumatic optic neuropathy.
    Razeghinejad MR; Rahat F; Bagheri M
    J Neurotrauma; 2010 Oct; 27(10):1905-9. PubMed ID: 20649490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of levodopa and carbidopa on visual function in patients with non-arteritic anterior ischaemic optic neuropathy.
    Simsek T; Eryilmaz T; Acaroglu G
    Int J Clin Pract; 2005 Mar; 59(3):287-90. PubMed ID: 15857324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene.
    Kaplan PW; Allen RP; Buchholz DW; Walters JK
    Sleep; 1993 Dec; 16(8):717-23. PubMed ID: 8165385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levodopa/carbidopa intestinal gel therapy for advanced Parkinson Disease: AN early toxic effect for small nerve fibers?
    Devigili G; Rinaldo S; Lettieri C; Eleopra R
    Muscle Nerve; 2016 Nov; 54(5):970-972. PubMed ID: 27514937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
    Ondo WG; Shinawi L; Moore S
    Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials.
    Mooney ME; Schmitz JM; Moeller FG; Grabowski J
    Drug Alcohol Depend; 2007 May; 88(2-3):214-23. PubMed ID: 17134849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Propionic acidaemia with basal ganglia stroke: treatment of acute extrapyramidal symptoms with L-DOPA.
    Burlina AP; Baracchini C; Carollo C; Burlina AB
    J Inherit Metab Dis; 2001 Oct; 24(5):596-8. PubMed ID: 11757587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
    Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
    J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of levodopa and carbidopa on non-motor symptoms and signs of Parkinson's disease.
    Rahman MM; Uddin MJ; Chowdhury JH; Chowdhury TI
    Mymensingh Med J; 2014 Jan; 23(1):18-23. PubMed ID: 24584367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
    Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
    Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
    J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G; Liss C; Reines S; Irr J; Nibbelink D
    Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.